Jag Paul Heer

USPTO Granted Patents = 17 (Patent Applications = 11)

CIPO Patents = 2 (Patent Applications = 13)

EPO Patents = 10 (Patent Applications = 17)

Average Co-Inventor Count = 4.3

ph-index = 4

Forward Citations = 42(Granted Patents)

Location History:

Brussels, BE (2018)
Slough Berkshire, GB (2020)
Slough, GB (2019 - 2024)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2018-2025

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12410161 - Tetrahydrobenzo-quinoline sulfonamides derivative compounds (2025-09-09),

2. 11912721 - Fused pentacyclic imidazole derivatives (2024-02-27),

3. 10953019 - Fused pentacyclic imidazole derivatives as modulators of TNF activity (2021-03-23),

4. 10906919 - Fused pentacyclic imidazole derivatives (2021-02-02),

5. 10793578 - Fused pentacyclic imidazole derivatives as modulators of TNF activity (2020-10-06),

6. 10766906 - Fused hexacyclic imidazole derivatives as modulators of TNF activity (2020-09-08),

7. 10669286 - Fused pentacyclic imidazole derivatives as modulators of TNF activity (2020-06-02),

8. 10669263 - Substituted benzimidazole derivative as a modulator of TNF activity (2020-06-02),

9. 10654861 - Fused pentacyclic imidazole derivatives as modulators of TNF activity (2020-05-19),

10. 10472362 - Fused tricyclic imidazo pyrazines as modulators of TNF activity (2019-11-12),

11. 10202405 - Fused pentacyclic imidazole derivatives (2019-02-12),

12. 10093652 - Tetrahydrobenzimidazole derivatives as modulators of TNF activity (2018-10-09),

13. 10087179 - Fused tricyclic imidazole derivatives as modulators of TNF activity (2018-10-02),

14. 9969728 - Tetrahydroimidazopyridine derivatives as modulators of TNF activity (2018-05-15),

15. 9932343 - Fused tricyclic benzimidazoles derivatives as modulators of TNF activity (2018-04-03),

Title: Jag Paul Heer: Innovator in Pharmaceutical Compounds

Introduction

Jag Paul Heer is a distinguished inventor based in Slough, GB, known for his significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 17 patents, he has made strides in developing innovative compounds aimed at treating various medical conditions.

Latest Patents

His latest patents include the invention of tetrahydrobenzo-quinoline sulfonamides derivative compounds. This invention relates to derivatives of formula (I) and outlines processes for preparing them, as well as pharmaceutical compositions containing these compounds. They are particularly useful in treating disorders caused by IgE, such as allergic responses and certain autoimmune responses. Another notable patent is for fused pentacyclic imidazole derivatives, which serve as potent modulators of human TNFa activity. These derivatives are beneficial in the treatment and prevention of a wide range of ailments, including autoimmune and inflammatory disorders, neurological disorders, and oncological disorders.

Career Highlights

Throughout his career, Jag Paul Heer has worked with reputable companies such as UCB Biopharma Srl and UCB Biopharma Sprl. His work in these organizations has allowed him to focus on innovative research and development in the pharmaceutical sector.

Collaborations

Jag has collaborated with notable coworkers, including Victoria Elizabeth Jackson and Jean Keyaerts, contributing to a dynamic and innovative work environment.

Conclusion

Jag Paul Heer exemplifies the spirit of innovation in the pharmaceutical industry through his extensive patent portfolio and collaborative efforts. His work continues to impact the treatment of various medical conditions, showcasing the importance of research and development in healthcare.

This text is generated by artificial intelligence and may not be accurate.